When kidneys are injured, CT contrast isn’t the culprit

Intravenous CT contrast does no harm to patients’ kidneys, according to a meta-analysis of 28 medical-journal articles involving more than 107,000 patients.

The study was published online Aug. 12 in Annals of Emergency Medicine.

Ryan Aycock, MD, of Eglin Air Force Base Hospital, Raveendhara Bannuru, MD, PhD, of Tufts University and colleagues searched PubMed and five other study aggregators for research reports presenting data on adverse effects in patients who received intravenous CT contrast versus those who had CT without contrast.

The team found contrast-enhanced CT was not significantly associated with either acute kidney injury (odds ratio 0.94), need for renal replacement therapy (odds ratio 0.83) or all-cause mortality (odds ratio 1.0).

“We found no significant differences in our principal study outcomes between patients receiving contrast-enhanced CT versus those receiving noncontrast CT,” the authors write. “Given similar frequencies of acute kidney injury in patients receiving noncontrast CT, other patient- and illness-level factors, rather than the use of contrast material, likely contribute to the development of acute kidney injury.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.